Loading quotes...
Forecast
The analysts' average price target is €39.89 (+27.04%). The median is €40.02 (+27.45%).
| Buy |
Â
25 |
| Hold |
Â
2 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Xencor: positive Phase‑1 data on XmAb819 spark 15% share surge
Clinical dose‑selection data for the kidney cancer candidate XmAb819 convinced investors and led to an about 15% rise in the share price. The company plans to start a potentially approval‑relevant study by the end of 2027. Available cash secures operations until at least 2029 and supports a revaluation of the biotech platform. » More on finanzen.net
Xencor shifts strategy to late-stage development focusing on XmAb819
At the Cantor Fitzgerald Healthcare Conference Xencor presented its transition from a platform licensor to a late-stage clinical developer and is concentrating on its in-house XmAb portfolio. Lead program XmAb819 for renal cell carcinoma showed an early objective response rate of 25%; an ESMO update in about a month should clarify dose selection and response duration and pave the way for a registration-relevant study in 2025. The company is stopping monotherapy development of XmAb541 in favor of combinatorial “AND-gate” approaches and is also advancing TL1A programs as well as partner projects with Astellas and Johnson & Johnson. » More on de.investing.com
Xencor hits 52-week high at $21.99
Xencor’s stock climbed to a 52-week high of $21.99 and is currently trading at $21.89, with an annual performance of +41% and a one-year gain of 178.71%. Five analysts have recently raised their earnings estimates, although the stock is trading above their fair‑value estimates. In addition, the phase-1 study of the bispecific antibody XmAb819 was accepted for presentation at the ESMO Congress (Oct. 23–27, 2026), with a focus on advanced clear‑cell renal cell carcinoma. » More on de.investing.com
Xencor hits 52-week high at $21.34
Xencor's stock is trading at $21.40, having reached a 52-week high of $21.34; the market capitalization is around $1.57 billion. The price has recovered strongly from its 52-week low of $6.92 and is up 154.93% over the past year, but InvestingPro currently estimates it to be trading above its fair value. Xencor also announced it will present Phase‑1 study results for XmAb819 at the ESMO Congress 2026; quarterly results follow in six days. » More on de.investing.com
Xencor reaches $105 million settlement with Alexion over Ultomiris U.S. royalties
Xencor has reached an agreement with Alexion on U.S. royalties for Ultomiris and will receive $105 million in two equal installments ($52.5 million in August, the remainder on the first anniversary). After the payment, Alexion is released from further obligations to pay royalties on U.S. Ultomiris sales; Xencor retains royalties on sales outside the U.S. CEO Bassil Dahiyat says the agreement creates immediate liquidity and reflects the value of the U.S. royalties expected through 2028. Xencor currently expects to have sufficient funds through 2028 under its plan and will update its year-end 2026 cash forecast with the Q2 results. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 102.87M | 474.89% |
| Gross profit | 102.87M | 461.79% |
| Net profit | 34.82M | 777.91% |
| EBITDA | 40.27M | 1,017.99% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.35B |
Number of shares | 75.04M |
52-week high/low | €36.93 - €9.44 |
| Dividends | No |
Beta | 0.90 |
P/E ratio | -21.90 |
PEG ratio | 0.30 |
P/B ratio | 4.68 |
P/S ratio | 12.87 |
Company profile
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. In addition, it is developing VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. Further, the company is developing AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
| Name | Xencor |
| CEO | Bassil I. Dahiyat |
| Headquarters | Pasadena,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 12/03/2013 |
| Employees | 260 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | XNCR |
Frankfurt | XE9.F |
DĂĽsseldorf | XE9.DU |
SIX | XE9.SW |
MĂĽnchen | XE9.MU |